The role of funding and policies on innovation in cancer drug development

Kanavos, Panos; Sullivan, Richard; Lewison, Grant; Schurer, Willemien; Eckhouse, Seth; Vlachopioti, Z.

doi:10.3332/ecancer.2010.164

Cited by 22 publications

(18 citation statements)

References 125 publications

(132 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Beyond the US, during 2006–2007, 153 European public funding organizations spent €603 million on direct cancer drug research and development. Moreover, the 21 US public funding organizations spent €1.7 billion during the same period [ 86 ]. Second, big programs can greatly promote the development of marine bioactivity research.…”

Section: Resultsmentioning

confidence: 99%

Statistical Research on the Bioactivity of New Marine Natural Products Discovered during the 28 Years from 1985 to 2012

et al. 2015

View full text Add to dashboard Cite

Every year, hundreds of new compounds are discovered from the metabolites of marine organisms. Finding new and useful compounds is one of the crucial drivers for this field of research. Here we describe the statistics of bioactive compounds discovered from marine organisms from 1985 to 2012. This work is based on our database, which contains information on more than 15,000 chemical substances including 4196 bioactive marine natural products. We performed a comprehensive statistical analysis to understand the characteristics of the novel bioactive compounds and detail temporal trends, chemical structures, species distribution, and research progress. We hope this meta-analysis will provide useful information for research into the bioactivity of marine natural products and drug development.

show abstract

Section: Resultsmentioning

confidence: 99%

Statistical Research on the Bioactivity of New Marine Natural Products Discovered during the 28 Years from 1985 to 2012

et al. 2015

View full text Add to dashboard Cite

show abstract

“…The current elevation of ‘international competitiveness’ by national and supranational governments as a (or perhaps ‘the’) primary concern for state policy may also be transforming the orientation of publicly-funded research in ways that are not in the best interests of patients or public health. There is evidence that public funding bodies, as well as the largest philanthropic funders, are concentrating resources on research to support drug discovery and development to the neglect of other types of investigation ( European Commission, 2007; FDA, 2004; Kanavos et al., 2010 ). One consequence of these shifts is that it is increasingly difficult for researchers to attract funding for applied clinical research questions that do not involve drugs ( Braga, 2011 , 2347).…”

Section: Understanding Trends In Drug Treatment: the Gap Between Rhetmentioning

confidence: 99%

Drugs, cancer and end-of-life care: A case study of pharmaceuticalization?

Davis

2015

Social Science & Medicine

View full text Add to dashboard Cite

There is evidence from some countries of a trend towards increasingly aggressive pharmacological treatment of patients with advanced, incurable cancer. To what extent should this be understood as a progressive development in which technological innovations address previously unmet needs, or is a significant amount of this expansion explained by futile or even harmful treatment? In this article it is argued that while some of this growth may be consistent with a progressive account of medicines consumption, part of the expansion is constituted by the inappropriate and overly aggressive use of drugs. Such use is often explained in terms of individual patient consumerism and/or factors to do with physician behaviour. Whilst acknowledging the role of physicians and patients' expectations, this paper, drawing on empirical research conducted in the US, the EU and the UK, examines the extent to which upstream factors shape expectations and drive pharmaceuticalisation, and explores the value of this concept as an analytical tool.

show abstract

“…Direct public funding plays a vital part in supporting fundamental biomedical research. In oncology, for example, recent work suggests that OECD-wide the majority of all such work is funded via governments together with (particularly in the UK) the voluntary sector [24]. But with regard to translating knowledge into effective products, research-based pharmaceutical companies also play a valuable part.…”

Section: Policy Recommendationsmentioning

confidence: 98%

Can (and will) Governments Afford Personalized Medicine?

Taylor

Al-Saeed

2010

Personalized Medicine

View full text Add to dashboard Cite

'Personalized' (or more specifically targeted) medicines promise aging populations important medium- to long-term benefits, including extended healthy life expectancies. But the time and resources needed to deliver such advances may be significantly greater than optimists expect. Given current methodologies, drugs for limited numbers of older patients are also much less likely to be judged cost effective than treatments for more common conditions in younger populations. There is a consequent danger that private and public funding for personalized medicine development will in the future fall to a level that is significantly below the global public's best interests. Policy-makers should be aware of this risk, and take actions to mitigate it. These include minimizing the costs and complexities associated with marketing personalized medicines and linked diagnostic tests, as well as strengthening intellectual property protection in ways that will allow 'rich world' pharmaceutical price moderation, increased innovator security and enhanced treatment access for poorer populations.

show abstract

The role of funding and policies on innovation in cancer drug development

Cited by 22 publications

References 125 publications

Statistical Research on the Bioactivity of New Marine Natural Products Discovered during the 28 Years from 1985 to 2012

Statistical Research on the Bioactivity of New Marine Natural Products Discovered during the 28 Years from 1985 to 2012

Drugs, cancer and end-of-life care: A case study of pharmaceuticalization?

Can (and will) Governments Afford Personalized Medicine?

Contact Info

Product

Resources

About